The value of a post-treatment whole body scan

Essentials of Thyroid Cancer Management

Volumn , Issue , 2005, Pages 65-68

  Amdur, Robert J ^a   Mazzaferri, Ernest L ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74249087421     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-25714-4_9     Document Type: Chapter

References (5)

1. Carlisle, MR, C Lu, and IR McDougall. 2003. The interpretation of I-131 scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun 24(6):715-735
2. Chung, JK, YJ Lee, JM Jeong, DS Lee, MC Lee, BY Cho, et al. 1997. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med 38:1191-1195
3. Mazzaferri, EL, and RT Kloos. 2001. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86(4):1447-1463
4. Mazzaferri, EL, RJ Robbins, CA Spencer, LE Braverman, F Pacini, L Wartofsky, BR Haugen, SI Sherman, DS Cooper, GD Braunstein, S Lee, TF Davies, BM Arafah, PW Ladenson, and A Pinchera. 2003. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88(4):1433-1441
5. Shapiro, B, V Rufini, A Jarwan, O Geatti, KJ Kearfott, LM Fig, ID Kirkwood, and MD Gross. 2000. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 30(2):115-32.